BioFire Diagnostics, LLC Sustainability Profile
BioFire Diagnostics, LLC, a prominent player in the molecular diagnostics industry, is headquartered in the United States. Founded in 1990, the company has established itself as a leader in infectious disease testing, particularly through its innovative BioFire FilmArray® system. This cutting-edge technology allows for rapid, comprehensive testing of multiple pathogens from a single patient sample, setting BioFire apart in the market. With a strong presence in North America and expanding operations globally, BioFire Diagnostics has achieved significant milestones, including FDA approvals for various products. The company’s commitment to accuracy and speed in diagnostics has earned it a notable reputation among healthcare professionals, making it a trusted partner in clinical laboratories. As a subsidiary of bioMérieux, BioFire continues to push the boundaries of diagnostic solutions, enhancing patient care worldwide.
DitchCarbon Score
How does BioFire Diagnostics, LLC's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
BioFire Diagnostics, LLC's score of 73 is higher than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
BioFire Diagnostics, LLC, headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of bioMérieux S.A., which cascades its climate commitments and performance metrics down to BioFire. While no direct emissions data is available, BioFire's climate initiatives are influenced by the targets set by its parent company, bioMérieux S.A. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP), both of which aim to enhance transparency and accountability in corporate climate action. As a subsidiary, BioFire aligns with the broader sustainability goals of bioMérieux, which are designed to reduce greenhouse gas emissions across various scopes. However, specific reduction targets or achievements for BioFire Diagnostics have not been disclosed. In summary, while BioFire Diagnostics, LLC does not provide its own emissions data or specific reduction targets, it is part of a corporate family that is actively engaged in climate commitments through bioMérieux S.A.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 31,000,000 | 00,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000 | 00,000 |
| Scope 2 | 35,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 241,000,000 | 000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000 | 0,000,000 |
How Carbon Intensive is BioFire Diagnostics, LLC's Industry?
How Carbon Intensive is BioFire Diagnostics, LLC's Location?
BioFire Diagnostics, LLC's Scope 3 Categories Breakdown
BioFire Diagnostics, LLC's Scope 3 emissions, which increased by 0% last year and decreased by approximately 100% since 2018, demonstrating supply chain emissions tracking. Their carbon footprint includes suppliers and value chain emissions, with Scope 3 emissions accounting for 3% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 54836% of Scope 3 emissions.
Top Scope 3 Categories
BioFire Diagnostics, LLC's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
BioFire Diagnostics, LLC has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
